Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21N5O2.C7H6O2 |
Molecular Weight | 461.5139 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cn1c(=O)cc(N2CCC[C@]([H])(C2)N)n(Cc3ccccc3C#N)c1=O.c1ccc(cc1)C(=O)O
InChI
InChIKey=KEJICOXJTRHYAK-XFULWGLBSA-N
InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1
Molecular Formula | C18H21N5O2 |
Molecular Weight | 339.3923 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C7H6O2 |
Molecular Weight | 122.1216 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.takeda.com/news/2013/20130924_5997.html;
http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705
Curator's Comment:: description was created based on several sources, including
https://www.takeda.com/news/2013/20130924_5997.html;
http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705
Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
CNS Activity
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002178/WC500152200.pdf
Curator's Comment:: Alogliptin is unlikely to have untoward pharmacologic activity in the central nervous system (CNS). Although alogliptin inhibited naloxone binding at nonselective opioid receptors in vitro in the rat cerebral cortex, it did not show any binding affinity for human receptors typically associated with abuse potential (human recombinant opiate receptors).
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17441705
Curator's Comment:: Alogliptin was discovered by Takeda’s wholly owned subsidiary, Takeda San Diego, Inc. # Takeda San Diego, Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | NESINA Approved UseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. Launch Date1.35907194E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
165 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/ |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
154.83 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
335.36 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
75.38 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
114.08 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
246 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
55.28 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/ |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1174.76 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
1625.58 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
2488.48 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
3389.21 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
601.65 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
842.17 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
1674.87999999999 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
3306.68 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
895.28 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/ |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
21 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
20.67 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
19.45 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
17 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
80% |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg single, oral Highest studied dose |
healthy, 26.6 years (range: 18-55 years) n = 5 Health Status: healthy Age Group: 26.6 years (range: 18-55 years) Sex: M Population Size: 5 Sources: |
|
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (6 patients) Sources: Dizziness (4 patients) Constipation (3 patients) |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Disc. AE: Acute myocardial infarction, Angina unstable... AEs leading to discontinuation/dose reduction: Acute myocardial infarction (8 patients) Sources: Page: p. 48Angina unstable (2 patients) Myocardial infarction (12 patients) Abdominal pain (2 patients) Diarrhea (1 patient) Nausea (3 patients) Edema peripheral (4 patients) Blood creatinine increased (6 patients) Creatinine renal clearance abnormal (3 patients) Creatinine renal clearance decreased (22 patients) Lipase increased (10 patients) Hyperglycemia (3 patients) Dizziness (4 patients) Headache (2 patients) Renal impairment (13 patients) Rash (2 patients) Rash pruritic (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Constipation | 3 patients | 400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Dizziness | 4 patients | 400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Headache | 6 patients | 400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Diarrhea | 1 patient Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Lipase increased | 10 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Myocardial infarction | 12 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Renal impairment | 13 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Abdominal pain | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Angina unstable | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Headache | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Rash | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Creatinine renal clearance decreased | 22 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Creatinine renal clearance abnormal | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Hyperglycemia | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Nausea | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Rash pruritic | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Dizziness | 4 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Edema peripheral | 4 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Blood creatinine increased | 6 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Acute myocardial infarction | 8 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0 |
inconclusive | no (co-administration study) Comment: cyclosporin does not have significant impact on plasma PK of SYR-322 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0 |
||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000PharmR.pdf#page=109 Page: 109.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. | 2007 May 17 |
|
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. | 2008 |
|
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. | 2008 Apr |
|
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. | 2008 Apr |
|
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. | 2008 Dec |
|
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. | 2008 Oct 27 |
|
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. | 2009 Jan |
|
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. | 2009 Jan |
|
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. | 2009 Jan 14 |
|
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. | 2009 Jul 17 |
|
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | 2009 Jul 20 |
|
Alogliptin: a new addition to the class of DPP-4 inhibitors. | 2009 Jul 21 |
|
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. | 2009 Jun |
|
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. | 2009 Mar |
|
Diabetes treatment. | 2009 Mar |
|
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. | 2009 Mar 1 |
|
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. | 2009 May |
|
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. | 2009 Nov |
|
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. | 2009 Nov |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | 2009 Oct |
|
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. | 2009 Oct |
|
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. | 2009 Sep |
|
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. | 2009 Sep 28 |
|
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. | 2009 Sep-Oct |
|
New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. | 2009 Sep-Oct |
|
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. | 2010 |
|
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). | 2010 |
|
Recommendations for management of diabetes during Ramadan: update 2010. | 2010 Aug |
|
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. | 2010 Aug |
|
Managing type 2 diabetes in the primary care setting: beyond glucocentricity. | 2010 Aug |
|
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. | 2010 Dec |
|
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. | 2010 Jan |
|
The evolving place of incretin-based therapies in type 2 diabetes. | 2010 Jul |
|
Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring. | 2010 Jul 1 |
|
The physiologic role of incretin hormones: clinical applications. | 2010 Mar |
|
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. | 2010 Mar |
|
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. | 2010 Mar 24 |
|
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. | 2010 May 10 |
|
Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. | 2010 Nov |
|
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. | 2010 Nov |
|
DPP-4 inhibitors: what may be the clinical differentiators? | 2010 Nov |
|
Alogliptin: a review of its use in the management of type 2 diabetes mellitus. | 2010 Oct 22 |
|
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. | 2010 Sep |
|
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. | 2010 Sep 7 |
|
Exenatide once weekly: clinical outcomes and patient satisfaction. | 2010 Sep 7 |
|
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. | 2012 Aug 1 |
|
Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. | 2012 Jun |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 09:49:32 UTC 2021
by
admin
on
Sat Jun 26 09:49:32 UTC 2021
|
Record UNII |
EEN99869SC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT000007
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
EEN99869SC
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
850649-62-6
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
1368000
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | RxNorm | ||
|
CHEMBL376359
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
M1572
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | Merck Index | ||
|
16088021
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
C75186
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
850649-62-6
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY | |||
|
SUB32165
Created by
admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |